A carregar...
EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer
BACKGROUND: As supplement to KRAS mutational analysis, BRAF and PIK3CA mutations as well as expression of PTEN may account for additional non-responders to anti-EGFR-MoAbs treatment. The aim of the present study was to investigate the utility as biomarkers of these mutations in a uniform cohort of p...
Na minha lista:
| Main Authors: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2011
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3073939/ https://ncbi.nlm.nih.gov/pubmed/21439039 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-11-107 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|